REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read...
The purchase allows the brain–computer interface company to oversee the end-to-end fabrication of its microelectrode array while iterating quickly on...
Dr. Mario Capecchi, Nobel Laureate at University of Utah, to Deliver Keynote on Research to Understand Symptoms Prevalent in Individuals...
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile...
Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023...
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral...
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed...
Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders...
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British...
Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical researchDURHAM, N.C., Sept. 20, 2023...
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,...
Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and...
Purchases All 5,323,451 Shares Validly Tendered at $0.70 per SharePALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) --...
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX FestivalVancouver, British Columbia--(Newsfile Corp. - September 13,...
-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science...
Press release, Helsinki, 13 September 2023 at 10 AM (EEST) Neuroscience Center in Sweden Orders Nexstim NBS 5 System Nexstim...